NASDAQ:GLSI

Greenwich LifeSciences Competitors

$31.24
-2.55 (-7.55 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.05
$34.16
50-Day Range
$29.99
$53.60
52-Week Range
$3.26
$158.07
Volume89,937 shs
Average Volume547,646 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Greenwich LifeSciences (NASDAQ:GLSI) Vs. JNJ, PFE, ABT, ABBV, NVS, and MRK

Should you be buying GLSI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Greenwich LifeSciences, including Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), AbbVie (ABBV), Novartis (NVS), and Merck & Co., Inc. (MRK).

Johnson & Johnson (NYSE:JNJ) and Greenwich LifeSciences (NASDAQ:GLSI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Johnson & Johnson and Greenwich LifeSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson021002.83
Greenwich LifeSciences00103.00

Johnson & Johnson presently has a consensus target price of $185.70, indicating a potential upside of 9.06%. Greenwich LifeSciences has a consensus target price of $75.00, indicating a potential upside of 140.08%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Johnson & Johnson.

Earnings & Valuation

This table compares Johnson & Johnson and Greenwich LifeSciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.46$15.12 billion$8.6819.62
Greenwich LifeSciencesN/AN/AN/AN/AN/A

Johnson & Johnson has higher revenue and earnings than Greenwich LifeSciences.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Johnson & Johnson and Greenwich LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Greenwich LifeSciencesN/AN/AN/A

Summary

Johnson & Johnson beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and Pfizer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Greenwich LifeSciences00103.00
Pfizer011202.15

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. Pfizer has a consensus target price of $39.6429, indicating a potential downside of 0.54%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Pfizer.

Valuation & Earnings

This table compares Greenwich LifeSciences and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenwich LifeSciencesN/AN/AN/AN/AN/A
Pfizer$51.75 billion4.30$16.27 billion$2.9513.51

Pfizer has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

67.4% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Greenwich LifeSciencesN/AN/AN/A
Pfizer17.85%24.88%9.32%

Summary

Pfizer beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and Abbott Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Greenwich LifeSciences00103.00
Abbott Laboratories121302.75

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. Abbott Laboratories has a consensus target price of $125.8125, indicating a potential upside of 5.78%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Abbott Laboratories.

Valuation & Earnings

This table compares Greenwich LifeSciences and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenwich LifeSciencesN/AN/AN/AN/AN/A
Abbott Laboratories$31.90 billion6.62$3.69 billion$3.2436.71

Abbott Laboratories has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Greenwich LifeSciencesN/AN/AN/A
Abbott Laboratories10.50%18.19%8.29%

Summary

Abbott Laboratories beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and AbbVie, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Greenwich LifeSciences00103.00
AbbVie121402.76

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. AbbVie has a consensus target price of $117.1250, indicating a potential upside of 0.78%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than AbbVie.

Valuation & Earnings

This table compares Greenwich LifeSciences and AbbVie's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenwich LifeSciencesN/AN/AN/AN/AN/A
AbbVie$33.27 billion6.17$7.88 billion$8.9413.00

AbbVie has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Greenwich LifeSciencesN/AN/AN/A
AbbVie18.16%439.24%13.22%

Summary

AbbVie beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and Novartis (NYSE:NVS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and Novartis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Greenwich LifeSciences00103.00
Novartis23702.42

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. Novartis has a consensus target price of $108.50, indicating a potential upside of 23.32%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Novartis.

Valuation & Earnings

This table compares Greenwich LifeSciences and Novartis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenwich LifeSciencesN/AN/AN/AN/AN/A
Novartis$47.50 billion4.24$11.73 billion$5.2416.79

Novartis has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

9.9% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and Novartis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Greenwich LifeSciencesN/AN/AN/A
Novartis14.71%24.39%10.59%

Summary

Novartis beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Greenwich LifeSciences (NASDAQ:GLSI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Analyst Ratings

This is a summary of current ratings for Merck & Co., Inc. and Greenwich LifeSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.02802.80
Greenwich LifeSciences00103.00

Merck & Co., Inc. currently has a consensus price target of $97.50, indicating a potential upside of 24.73%. Greenwich LifeSciences has a consensus price target of $75.00, indicating a potential upside of 140.08%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Merck & Co., Inc..

Earnings & Valuation

This table compares Merck & Co., Inc. and Greenwich LifeSciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.22$9.84 billion$5.1915.06
Greenwich LifeSciencesN/AN/AN/AN/AN/A

Merck & Co., Inc. has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Merck & Co., Inc. and Greenwich LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Greenwich LifeSciencesN/AN/AN/A

Summary

Merck & Co., Inc. beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.


Greenwich LifeSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.3$170.27-1.0%$448.39 billion$82.06 billion26.77
Pfizer logo
PFE
Pfizer
2.1$39.86-0.7%$222.32 billion$51.75 billion25.72Earnings Announcement
Analyst Report
Analyst Revision
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$118.94-0.0%$211.33 billion$31.90 billion62.93
AbbVie logo
ABBV
AbbVie
2.7$116.22-0.4%$205.11 billion$33.27 billion24.57Analyst Report
Novartis logo
NVS
Novartis
2.0$87.98-0.0%$201.36 billion$47.50 billion28.47
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$78.17-0.3%$197.80 billion$46.84 billion17.29
Eli Lilly and logo
LLY
Eli Lilly and
2.1$194.76-0.3%$186.78 billion$22.32 billion31.82Buyback Announcement
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.2$76.28-0.8%$179.62 billion$18.30 billion28.68Earnings Announcement
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$64.70-0.4%$144.47 billion$26.15 billion-588.13
AstraZeneca logo
AZN
AstraZeneca
2.2$54.38-1.0%$142.73 billion$24.38 billion56.65
Sanofi logo
SNY
Sanofi
1.4$52.45-1.2%$132.07 billion$40.00 billion22.41
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$38.53-0.5%$103.75 billion$43.10 billion11.86Dividend Increase
Zoetis logo
ZTS
Zoetis
1.8$171.17-0.2%$81.30 billion$6.26 billion50.79Earnings Announcement
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$212.90-1.0%$55.11 billion$4.16 billion26.88
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.34-1.1%$53.82 billion$7.86 billion18.36Earnings Announcement
Insider Selling
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.96-0.5%$53.52 billion$30.20 billion56.54Upcoming Earnings
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$171.81-0.8%$37.97 billion$4.99 billion40.14Analyst Revision
BeiGene logo
BGNE
BeiGene
1.3$303.32-2.9%$27.81 billion$428.21 million-15.01Earnings Announcement
Analyst Report
Analyst Revision
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$41.49-1.3%$25.19 billionN/A0.00
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.24-0.4%$24.42 billion$804.57 million28.87Earnings Announcement
Analyst Revision
CureVac logo
CVAC
CureVac
0.7$105.79-5.1%$19.77 billionN/A0.00Gap Up
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$86.24-2.0%$19.38 billion$1.30 billion23.56Earnings Announcement
Catalent logo
CTLT
Catalent
1.7$104.80-2.6%$17.85 billion$3.09 billion66.75Earnings Announcement
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.24-2.0%$15.24 billion$3.07 billion-56.56Earnings Announcement
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$128.63-2.1%$15.12 billion$219.75 million-16.43
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.39-1.8%$13.96 billion$1.70 billion17.48Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$149.45-5.8%$13.33 billion$12.98 million-49.32
Grifols logo
GRFS
Grifols
1.3$18.60-2.0%$12.79 billion$5.71 billion16.61Earnings Announcement
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$72.20-1.6%$12.01 billion$2.32 billion59.67
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.25-1.5%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$176.10-0.9%$10.02 billion$2.16 billion55.55Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
2.1$27.53-2.0%$9.87 billion$8.60 billion-5.05
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.82-3.7%$9.23 billionN/A0.00News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$189.88-2.9%$8.51 billion$1.45 billion17.96Earnings Announcement
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$147.63-2.5%$7.58 billion$3.34 million-19.17Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$109.25-4.8%$7.37 billion$103.71 million-24.89Earnings Announcement
Analyst Report
Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$130.07-2.2%$6.99 billion$14.98 million-15.84Upcoming Earnings
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$46.47-3.4%$6.94 billion$40.56 million-13.63Earnings Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.10-0.4%$6.88 billion$87.99 million-78.69Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$43.12-0.4%$5.76 billion$4.84 billion-718.55
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.03-6.5%$5.59 billion$380.83 million-8.96Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.21-2.9%$5.38 billion$66.51 million17.01
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$37.90-6.1%$5.36 billion$150,000.00-17.88News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.24-0.8%$5.11 billion$1.12 billion75.50Earnings Announcement
Allakos logo
ALLK
Allakos
1.7$94.95-6.3%$5.08 billionN/A-34.65News Coverage
Galapagos logo
GLPG
Galapagos
1.3$73.54-2.0%$4.82 billion$1.00 billion-11.14Analyst Report
Gap Down
Schrödinger logo
SDGR
Schrödinger
1.6$64.01-6.8%$4.48 billion$85.54 million0.00News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.89-0.2%$4.38 billion$6.87 million-7.24Earnings Announcement
Analyst Revision
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$69.34-3.0%$4.30 billionN/A-5.65Earnings Announcement
News Coverage
Gap Down
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.